Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.
作者信息
Hughes Jing, Vudattu Nalini, Sznol Mario, Gettinger Scott, Kluger Harriet, Lupsa Beatrice, Herold Kevan C
机构信息
Department of Immunobiology, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT Section of Endocrinology and Metabolism, Yale University School of Medicine, New Haven, CT.
Department of Immunobiology, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT.
出版信息
Diabetes Care. 2015 Apr;38(4):e55-7. doi: 10.2337/dc14-2349.
Abstract
摘要
相似文献
1
Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.抗PD-1免疫疗法引发自身免疫性糖尿病
Diabetes Care. 2015 Apr;38(4):e55-7. doi: 10.2337/dc14-2349.
2
Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in 'anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes.在“抗程序性细胞死亡蛋白 1 抗体诱导”暴发性 1 型糖尿病中，停止抗程序性细胞死亡蛋白 1 抗体治疗可能会保留内在胰岛素分泌能力。
J Diabetes Investig. 2018 Mar;9(2):448-449. doi: 10.1111/jdi.12662.
3
PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.PD-1 抑制剂免疫相关不良事件在伴有内分泌自身免疫的患者中的表现。
J Clin Endocrinol Metab. 2018 Oct 1;103(10):3589-3592. doi: 10.1210/jc.2018-01430.
4
Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.免疫治疗（抗 PD-1 和/或抗 CTLA-4）治疗转移性黑色素瘤患者中 1 型和 2 型糖尿病的发生：一项回顾性研究。
Cancer Immunol Immunother. 2018 Aug;67(8):1197-1208. doi: 10.1007/s00262-018-2178-0. Epub 2018 May 28.
5
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.癌症免疫治疗期间与抗程序性死亡蛋白1相关的肺炎
N Engl J Med. 2015 Jul 16;373(3):288-90. doi: 10.1056/NEJMc1505197.
6
Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes.导致1型糖尿病的抗程序性死亡蛋白1和抗程序性死亡配体1单克隆抗体
Diabetes Care. 2015 Sep;38(9):e137-8. doi: 10.2337/dc15-0889. Epub 2015 Jun 26.
7
Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.抗程序性细胞死亡蛋白-1 治疗相关暴发性 1 型糖尿病。
J Diabetes Investig. 2016 Nov;7(6):915-918. doi: 10.1111/jdi.12531. Epub 2016 May 31.
8
A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient.一名具有遗传易感性的患者在接受抗PD1免疫治疗后发生暴发性1型糖尿病的病例。
Immunotherapy. 2017 Jun;9(7):531-535. doi: 10.2217/imt-2017-0020.
9
Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.在接受程序性死亡1受体免疫疗法治疗转移性恶性肿瘤的患者中诱发无痛性甲状腺炎。
J Clin Endocrinol Metab. 2015 May;100(5):1738-41. doi: 10.1210/jc.2014-4560. Epub 2015 Mar 9.
10
Efficacy of PD-1 blockade in tumors with MMR deficiency.PD-1阻断在错配修复缺陷肿瘤中的疗效。
Immunotherapy. 2016;8(1):1-3. doi: 10.2217/imt.15.97. Epub 2015 Dec 8.
引用本文的文献
1
PD-1 Bispecific Killer Engager (PD-1 BiKE) effectively depletes effector T lymphocytes in experimental autoimmune encephalomyelitis.程序性死亡蛋白1双特异性杀伤衔接分子（PD-1双特异性衔接分子，PD-1 BiKE）可有效耗竭实验性自身免疫性脑脊髓炎中的效应性T淋巴细胞。
Front Immunol. 2025 Aug 13;16:1644903. doi: 10.3389/fimmu.2025.1644903. eCollection 2025.
2
Rapid Onset of Fulminant Type 1 Diabetes 10 Days After the First Dose of Nivolumab: A Case Report.首次使用纳武单抗10天后暴发性1型糖尿病快速发病：一例报告
Cureus. 2025 Jun 13;17(6):e85957. doi: 10.7759/cureus.85957. eCollection 2025 Jun.
3
Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment.用于靶向清除PD-1阳性淋巴细胞的双特异性杀伤衔接器：自身免疫性疾病治疗的新途径。
Acta Pharm Sin B. 2025 Mar;15(3):1230-1241. doi: 10.1016/j.apsb.2024.10.014. Epub 2024 Nov 4.
4
Utility of Estimating Glycated Hemoglobin in Sodium Fluoride Tube and by Turbidimetric Immunoinhibition Method: Our Experience in a Tertiary Care Cancer Centre.氟化钠管中糖化血红蛋白估计及比浊免疫抑制法的效用：我们在三级癌症中心的经验。
Cureus. 2025 Mar 25;17(3):e81164. doi: 10.7759/cureus.81164. eCollection 2025 Mar.
5
Onset of Type 1 Diabetes Mellitus Five Months After Pembrolizumab Therapy for Nodular Melanoma: A Case Report.帕博利珠单抗治疗结节性黑色素瘤五个月后发生1型糖尿病：一例报告
Cureus. 2025 Mar 5;17(3):e80083. doi: 10.7759/cureus.80083. eCollection 2025 Mar.
6
Enhancing anti-CD3 mAb-mediated diabetes remission in autoimmune diabetes through regulation of dynamin-related protein 1(Drp1)-mediated mitochondrial dynamics in exhausted CD8T-cell subpopulations.通过调节耗竭性CD8T细胞亚群中发动蛋白相关蛋白1（Drp1）介导的线粒体动力学，增强抗CD3单克隆抗体介导的自身免疫性糖尿病缓解。
BMC Med. 2025 Mar 31;23(1):189. doi: 10.1186/s12916-025-04001-5.
7
Disease-modifying pharmacological treatments of type 1 diabetes: Molecular mechanisms, target checkpoints, and possible combinatorial treatments.1型糖尿病的疾病修饰性药物治疗：分子机制、靶点检查点及可能的联合治疗
Pharmacol Rev. 2025 Mar;77(2):100044. doi: 10.1016/j.pharmr.2025.100044. Epub 2025 Jan 23.
8
A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis.免疫检查点抑制剂相关糖尿病综述：发病机制、临床特征、治疗和预后。
Front Immunol. 2024 Nov 4;15:1448728. doi: 10.3389/fimmu.2024.1448728. eCollection 2024.
9
Usefulness of urine dipstick test in the management of adverse events associated with immune checkpoint inhibitors.尿液试纸检测在免疫检查点抑制剂相关不良事件管理中的作用。
Support Care Cancer. 2024 Oct 18;32(11):735. doi: 10.1007/s00520-024-08928-y.
10
Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment.免疫检查点抑制剂治疗后2型辅助性T细胞炎症性疾病的综述
Biomedicines. 2024 Aug 19;12(8):1886. doi: 10.3390/biomedicines12081886.
本文引用的文献
1
Nivolumab in previously untreated melanoma without BRAF mutation.纳武利尤单抗治疗未经 BRAF 突变检测的初治黑色素瘤。
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
2
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.抗 PD-L1 抗体在晚期癌症患者中的安全性和活性。
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
3
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
4
Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers.使用组合 MHC 多聚体同时检测针对不同胰岛细胞相关表位的循环自身反应性 CD8+ T 细胞。
Diabetes. 2010 Jul;59(7):1721-30. doi: 10.2337/db09-1486. Epub 2010 Mar 31.
5
Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies.监测 1 型糖尿病患者用抗 CD3 单克隆抗体治疗后抗原特异性 CD8 T 细胞的情况。
Clin Immunol. 2010 Feb;134(2):121-9. doi: 10.1016/j.clim.2009.09.005.
Zotero 插件